BRAF and melanoma: Several drugs are approved for malignant melanoma, including nivolumab (an antibody against PD-1), the proto-oncogene B-Raf inhibitor vemurafenib, ipilimumab (which targets CTLA-4), and the mitogen-activated extracellular kinase inhibitor trametinib [18].